Steven A. Feldman BA, MPH, PhD

Dr. Feldman directs the Surgery Branch Vector Production Facility, which develops and manufactures cGMP quality retroviral and lentiviral vectors encoding T cell receptors or chimeric antigen receptors for the ex vivo genetic modification of T lymphocytes in support of the Branch’s clinical efforts utilizing adoptive cell transfer for the treatment of patients with solid cancers and hematologic malignancies.

Dr. Feldman’s research interests also include development of retroviral and lentiviral packaging cell lines and novel strategies for the large-scale closed cell culture processes to support production of clinical reagents. As a result, the lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors. Recently, research efforts have been focused on individualized cell therapies targeting immunogenic mutations presented on breast cancers.